Drug intelligence / Profile preview

recombinant erythropoiesis stimulating protein

Development stage: Unknown
Lead developer: Shenyang Sunshine Pharmaceutical Co., LTD.
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous Infusion, Subcutaneous Injection, Intravenous Infusion

Overview

Recombinant erythropoiesis stimulating protein is a recombinant human erythropoietin produced in CHO cells. It is a high glucose, medium and long-acting recombinant protein product, containing 165 amino acids with 3 added glycosylation sites. This protein exhibits the same biological effects as natural erythropoietin, primarily stimulating erythropoiesis.

Other names: Recombinant Erythropoiesis Stimulating Protein Injection (CHO cell)Human Erythropoiesis Injection (CHO cell)rESP

Targets

Erythropoietin Receptor

Beyond the preview

Go deeper on recombinant erythropoiesis stimulating protein.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant erythropoiesis stimulating protein.

Explore the full profile